All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, March 7, 2021
Home » Blogs » BioWorld Perspectives » Casting Calls for Pfizer: The Movie

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld

Casting Calls for Pfizer: The Movie

Nov. 11, 2011
By Mike Williams
No Comments

In the August 15, 2011, issue of Fortune, the story “Inside Pfizer’s palace coup” provided a detailed account of the ouster of Jeff Kindler, CEO of Pfizer Inc. until December 2010.

Some watchers of Pfizer’s R&D efforts are victims of several “brutal layoffs” within the company. Others are pharma outsiders who debated with management as to whether there actually was a “Pfizer model of drug discovery” and, if so, the advisability of trying to emulate it.

The description of Pfizer as a “dysfunctional pharmaceutical giant” and the drama and politics of Kindler’s ouster came as confirmation that Pfizer was no better than any other pharma in ensuring the sustainability of its pipeline especially with its “ossified culture.”

Makings of a Best-Selling Movie

The Fortune piece has all the makings of a best seller along the lines of Smartest Guys in The Room (Enron), Barbarians at the Gate (RJR) or Too Big To Fail (Wall Street). The elements for a great movie that would appeal to the general public also are present: money; the politically adept; a micromanaging, indecisive and abrasive CEO; the antagonistic and manipulative head of HR, primary confidant of the CEO; and the éminence grise in the form of a previous CEO. Oh ? and money. An actual character for the head of R&D, “a ship passing in the night” is not covered in the article.

In considering a movie, much amusement can be derived in contemplating actors for the lead character roles. The Kindler part would be well served by Donald Sutherland reprising his politically adept, ruthless CEO role in Disclosure.

Based on the article, the HR head would be a natural for Meryl Streep ? not a reprise of her bubbly performance in Mamma Mia, but an amalgam of parts she has deliciously (The Devil Wears Prada) and maliciously (Doubt) played.

The éminence grise would be a perfect role – minus the gun ? for Edward Fox (The Day of the Jackal).

Casting the head of R&D ? like that in real-world Pfizer ? is challenging given that three individuals held this role in the five years or so that Kindler was CEO. While many researchers might consider Bruce Willis or Tom Cruise playing this role, Tom Hanks reprising his role as the improbable Robert Langdon from The Da Vinci Code would be a better candidate as might Russell Crowe (The Insider) or Matt Damon (The Informant!)

The options remain endless. Notwithstanding, the Pfizer palace coup may be a timely, if not enjoyable movie as it documents the case against pharma megamergers, the cadres of “outsourced” scientists in Ann Arbor, Fresnes, Groton and Sandwich and the helicopters traversing the East Coast.

By Mike Williams, BioWorld Perspectives contributing writer

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 5.
  • Gloved hand places sample tubes in PCR system

    COVID-19 test makers are adapting for variants

    BioWorld MedTech
    As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for March 5.
  • Coronavirus vaccine/therapeutics illustration

    Tonix looks to the past for the future of COVID-19 vaccines and testing

    BioWorld MedTech
    Tonix Pharmaceuticals Holding Corp. is looking to lessons from tuberculosis and smallpox to guide its future in infectious diseases. The company is developing an...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing